Search Press releases Keywords From To 10 Dec 2019 UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting Read More 6 Dec 2019 Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira[®] Read More 15 Nov 2019 Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study Read More 8 Nov 2019 Transparency notifications BlackRock, Inc. Read More 8 Nov 2019 UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP Read More 18 Oct 2019 Transparency notification Vanguard Health Care Fund Read More Pagination First page Previous page Previous … Page 53 Page 54 Page 55 Page 56 Current page 57 Page 58 Page 59 Page 60 Page 61 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
